ArticleTranslational cancer research2025
Factors affecting chemotherapy-induced peripheral neuropathy in patients with breast cancer: a cross-sectional study in China.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chemotherapy-induced peripheral neuropathy (CIPN) affects a substantial proportion of breast cancer patients and can lead to treatment delays and impaired quality of life (QoL). This study explored the burden of CIPN and the factors that influence it in patients with breast cancer. Methods: Convenience sampling was used from June 2022 to June 2024 to recruit women diagnosed with breast cancer at the breast surgery department of a large tertiary hospital in Beijing, China. Multivariate linear regression analysis was conducted to determine the factors linked to CIPN in a cohort of 130 eligible breast cancer patients. Results: The main factors associated with CIPN were age (β=0.35, P=0.004; β=0.60, P<0.001), monthly income ≥5,000 yuan (β=8.46, P=0.03; β=15.43, P=0.008), human epidermal growth factor receptor 2 positive (HER-2+) and hormone receptor negative (HR-) (β=-11.16, P=0.04), luminal B (β=-11.04, P=0.01), cancer diagnosis duration >7 months (β=10.71, P=0.01), and higher levels of anxiety (β=1.53, P=0.01). Conclusions: Clinicians and nurses should actively monitor patients for factors associated with CIPN during chemotherapy. Although interventions to improve QoL and enhance social support have been linked to lower CIPN severity, their causal impact on CIPN occurrence is not established and requires evaluation in future longitudinal studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.